HEXVIX VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.

Trial Profile

HEXVIX VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2012

At a glance

  • Drugs Mitomycin; Mitomycin
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms HELENA
  • Most Recent Events

    • 10 Nov 2012 Planned end date changed from 8 Sep 2011 to 8 Jan 2015 as reported by European Clinical Trials Database.
    • 15 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top